Magnetic-nanowaxberry-based microfluidic ExoSIC for affinity and continuous separation of circulating exosomes towards cancer diagnosis. Issue 6 (15th February 2023)

• Record Type: Journal Article
• Authors: Ding, Lihua; Liu, Xia; Zhang, Zhenzhong; Liu, Li-e; He, Sitian; Wu, Yan; Effah, Clement Yaw; Yang, Ruiying; Zhang, Aiai; Chen, Wensi; Yarmamat, Mubarak; Qu, Lingbo; Yang, Xiaonan; Wu, Yongjun
• Is Part Of: Lab on a chip. Volume 23:Issue 6(2023)
• Page Start: 1694
• Page End: 1702
• Publication Date: 2023-02-15
• Subjects: Miniature electronic equipment -- Periodicals; Combinatorial chemistry -- Periodicals; Biotechnology -- Periodicals; 543.0813
• DOI: 10.1039/d2lc00996j
• Languages: English
• ISSNs: 1473-0197

Abstract

Abstract : A novel irregular serpentine channel microfluidic chip based on magnetic-nanowaxberry was developed to continuously separate plasma exosomes with large yield and optimum purity. It can be successfully applied to cancer diagnosis with high accuracy. Abstract : Exosomes are seen as promising biomarkers for minimally invasive liquid biopsies and disease surveillance. However, the complexity of body fluids, inherent heterogeneity, and tiny size of exosomes impede their extraction, consequently restricting their clinical application. In this study, in order to efficiently isolate exosomes from clinical samples, an irregular serpentine channel microfluidic chip (ExoSIC) was designed to continuously separate exosomes from plasma based on a magnetic-nanowaxberry (MNWB). In the ExoSIC, irregular serpentine microchannels are utilized to increase fluid chaotic mixing, hence improving exosome capture efficiency. In comparison to commonly used spherical magnetic particles, the designed MNWB can not only enhance the capture efficiency of exosomes, but also possess a size-exclusion effect to improve exosome purity. Consequently, the ExoSIC exhibited a large yield (24 times higher than differential centrifugation), optimum purity (greater than precipitation and similar to differential centrifugation), and high specificity. Furthermore, the ExoSIC was utilized for plasma-based cancer diagnosis by multiplex monitoring of five exosomal biomarkers (exosomal concentration, EGFR, EpCAM, SAA1 and FV), and the AUC reached 0.791. This work provides a comprehensive framework for exosome-based cancer diagnostics in order to meet clinical requirements for exosome isolation and downstream analysis.